CTOs on the Move

Synaptogenix

www.synaptogen.com

 
Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.synaptogen.com
  • 1185 Avenue of the Americas 3rd Floor
    New York, NY USA 10036
  • Phone: 973.242.0005

Executives

Name Title Contact Details

Funding

Synaptogenix raised $14M on 01/21/2021
Synaptogenix raised $12.5M on 06/14/2021

Similar Companies

Xilio Therapeutics

Xilio is a Waltham, Massachusetts-based biopharmaceutical company focused on defeating cancer. The company`s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. Xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer.

Dewpoint Therapeutics

Dewpoint Therapeutics is leveraging a transformative shift in the understanding of cellular biology regulation to discover and advance breakthrough small-molecule therapeutics.

Renaissance RX

Renaissance RX is on the forefront of the new era of personalized medicine. The laboratory provides Pharmacogenetic Testing and Advanced Toxicology to give doctors unique insight into each individual patient with the most accurate and actionable information. The results are healthier patients and more successful medical practices. To compliment lab services and help ensure drug adherence, Renaissance RX offers access to its online medication portal and the Virtual PharmD Intelligence Engine.

MicroBiotix

MicroBiotix is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sigilon

Sigilon Therapeutics’ mission is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases. We're based in Cambridge, Mass.